Emerging data suggest this peptide, a dual stimulator targeting both GLP-1 and another hormone, may represent a significant development for obesity treatment. Early clinical tests have demonstrated impressive losses in abdominal mass , potentially surpassing other weight-loss therapies . Despite this, additional evaluation is needed to completely a